Description
ROS1 is a receptor tyrosine kinase that is frequently involved in genetic rearrangement in a variety of human cancers (e.g. NSCLC, gastric cancer, ovarian cancer, cholangiocarcinoma, colorectal cancer, angiosarcoma...). The resulting fusion protein harbors the constitutively active ROS1 kinase domain and drives cellular proliferation (Davies et. al.). In NSCLC about 1% harbor a ROS1 rearrangement. These patients are predominantely female and have a lower T-stage (Warth et. al.). Treatment with crizotinib leads to a reported objective response rate of appr. 70% and a median duration of response of 18 months (Shaw et. al.). Resistance mechanisms to crizotinib have been described and involve mutations in the kinase domain. More selective inhibitors of ROS1 might overcome this resistance (Davare et. al.).
Cyan = gene · Slate = variant · Green = drug · Click variant to filter table
Variants (4)
| CIViC ID | Name | HGVS | Type(s) |
|---|---|---|---|
| 1271 | G2032R GLY2032ARG,GLY2026ARG,GLY2028ARG,G2026R,G2028R,RS1057519788 | NC_000006.11:g.117638347C>T,NM_002944.2:c.6094G>A,NP_002935.2:p.Gly2032Arg,ENST00000368508.3:c.6094G>A,NM_001378902.1:c.6076G>A,NP_001365831.1:p.Gly2026Arg,NP_001365820.1:p.Gly2028Arg,NM_001378891.1:c.6082G>A,NC_000006.12:g.117317184C>T,ENST00000368507.8:c.6076G>A | missense_variant |
| 518 | G2101A GLY2095ALA,G2095A,GLY2101ALA | NC_000006.11:g.117631376C>G,ENST00000368508.3:c.6302G>C,NM_002944.2:c.6302G>C,NP_002935.2:p.Gly2101Ala,ENST00000368507.8:c.6284G>C,NM_001378902.1:c.6284G>C,NP_001365831.1:p.Gly2095Ala | missense_variant |
| 516 | L2026M LEU2026MET | NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A,NM_002944.2:c.6076C>A,NP_002935.2:p.Leu2026Met | missense_variant |
| 517 | L2155S L2149S,LEU2155SER,LEU2149SER | NC_000006.11:g.117630062A>G,NM_002944.2:c.6464T>C,NP_002935.2:p.Leu2155Ser,ENST00000368508.3:c.6464T>C,ENSP00000357493.3:p.Leu2149Ser,NP_001365831.1:p.Leu2149Ser ,ENST00000368507.8:c.6446T>C,NM_001378902.1:c.6446T>C | missense_variant |